Methods and compositions for providing cardiac protection
The invention provides a method of treating a cardiac disease by administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient. The compound capable of inhibiting AC5 may be administered singly or in combination with another agent, such as, for instance a β-blocker. In some embodiments, the AC5 inhibiting compound is 9-β-D-arabinofuranosyladenine (AraAde). The compound may be administered in an amount of about 1 to about 200 mg/kg/day, about 1 to about 100 mg/kg/day, about 10 to about 80 mg/kg/day, about 12 to about 40 mg/kg/day or about 15 to about 25 mg/kg/day. In some embodiments, the compound is administered parenterally. The cardiac disease may be, for instance, myocardial infarction (MI) or heart failure (HF). The compound capable of inhibiting AC5 may be administered alone or in conjunction with one or more other active agents. Likewise, the invention provides a method of treating a heart attack, a method of inhibiting myocardial apoptosis, and a method of treating heart failure by administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient in the same manner.
1 . A method of treating a cardiac disease comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient.
2 . A method according to claim 1 wherein the AC5 inhibiting compound is 9-β-9-β-arabinofuranosyladenine (AraAde).
3 . A method according to claim 1 wherein the AC5 inhibiting compound is administered in an amount of about 1 to about 100 mg/kg/day.
4 . A method according to claim 1 wherein the AC5 inhibiting compound is administered in an amount of about 10 to about 40 mg/kg/day.
5 . A method according to claim 1 wherein the AC5 inhibiting compound is administered in an amount of about 15 to about 25 mg/kg/day.
6 . The method of claim 1 wherein the compound is administered parenterally.
7 . A method of treating a heart attack comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient.
8 . A method according to claim 7 wherein the AC5 inhibiting compound is 9-β-9-β-arabinofuranosyladenine (AraAde).
9 . A method according to claim 7 wherein the AC5 inhibiting compound is administered in an amount of about 1 to about 100 mg/kg/day.
10 . A method according to claim 7 wherein the AC5 inhibiting compound is administered in an amount of about 10 to about 40 mg/kg/day.
11 . A method according to claim 7 wherein the AC5 inhibiting compound is administered in an amount of about 15 to about 25 mg/kg/day.
12 . The method of claim 7 wherein the compound is administered parenterally.
13 . A method of inhibiting myocardial apoptosis comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient.
14 . A method according to claim 13 wherein the AC5 inhibiting compound is 9-β-9-β-arabinofuranosyladenine (AraAde).
15 . A method according to claim 13 wherein the AC5 inhibiting compound is administered in an amount of about 1 to about 100 mg/kg/day.
16 . A method according to claim 13 wherein the AC5 inhibiting compound is administered in an amount of about 10 to about 40 mg/kg/day.
17 . A method according to claim 13 wherein the AC5 inhibiting compound is administered in an amount of about 15 to about 25 mg/kg/day.
18 . The method of claim 13 wherein the compound is administered parenterally.
19 . A method of treating heart failure comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient.
20 . A method according to claim 19 wherein the AC5 inhibiting compound is 9-β-9-β-arabinofuranosyladenine (AraAde).
21 . A method according to claim 19 wherein the AC5 inhibiting compound is administered in an amount of about 1 to about 100 mg/kg/day.
22 . A method according to claim 19 wherein the AC5 inhibiting compound is administered in an amount of about 10 to about 40 mg/kg/day.
23 . A method according to claim 19 wherein the AC5 inhibiting compound is administered in an amount of about 15 to about 25 mg/kg/day.
24 . The method of claim 19 wherein the compound is administered parenterally.
25 . The method of claim 1 wherein the cardiac disease is selected from the group consisting of heart attack and heart failure.